#generics

Class action lawsuit challenges deals that limit generic drug competition; Gilead says the case is without merit.

Pharma giants made agreements to keep prices high and block competition for generics, the civil lawsuit alleges.

At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.

Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.

The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.

U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.

Stocks of drug companies are rising—and that’s not a good sign for consumers.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

The FDA commissioner wants drugmakers to “end the shenanigans.”

This marks the manufacturer’s fifth generic antiretroviral launch.

AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.

The company is losing its exclusive rights to two HIV drugs: Reyataz and Sustiva.

However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”

Scott Gottlieb has said he wants lower costs and faster drug approvals.

The switch doesn’t appear to compromise the efficacy of antiretroviral treatment.

The country supplies generic meds to much of the world—but thanks to a new law, not for its own citizens living with HIV.